MGLL and early-onset autosomal dominant Alzheimer disease: JZL184, a selective inhibitor of monoacylglycerol lipase (MAGL), an enzyme that degrades eCB 2-arachidonoylglycerol (2-AG) [14,15], demonstrates neuroprotective effects against neurodegeneration in mouse models of Alzheimer’s disease [16] and PD [17].